Long-term efficacy of Stellest confirmed

New six-year data confirms long-term efficacy of Essilor® Stellest® lenses in slowing myopia progression

Essilor® recently unveiled new six-year clinical data of Essilor® Stellest® lenses, reinforcing the long-term efficacy of the lenses in managing myopia progression and axial elongation in children and young adults. The results underscore the significant and sustained impact of Essilor® Stellest® lenses in controlling myopia progression, offering valuable insights into strategies for addressing the global myopia epidemic.

The study began in 2018 with children aged between 8 and 13 years old. After completing the initial five-year phase, participants continued wearing Essilor® Stellest® lenses for an additional two years to assess the long-term impact on myopia progression. By the time of the sixth-year follow-up, the participants were aged between 14 and 19 years. The six-year results showed that Essilor® Stellest® lenses slowed myopia progression by 1.95 D (57%) and slowed axial elongation by 0.81 mm (52%)¹ on average, compared to an extrapolated single-vision lens control group* model based on data from the first two years of the clinical trial. The findings demonstrate the continued efficacy of Essilor® Stellest® lenses, with effects sustained up to 19 years of age.

“The positive response from eye care professionals highlights the widespread adoption of Essilor® Stellest® lenses as a trusted, proven tool for them worldwide, supporting long-term myopia management, while addressing the global myopia epidemic,” said Olga Prenat, Head of Medical & Professional Affairs at EssilorLuxottica. “These results reinforce EssilorLuxottica’s commitment to advancing myopia management with innovative solutions that have a lasting impact on children’s long-term eye health.”

In addition, five-year efficacy data recently published in Eye and Vision demonstrated that Essilor® Stellest® lenses significantly slowed myopia progression and axial elongation over five years, *² saving an average of three years of myopia development^{† 2,3}. The study also showed that the risk of progressing to high myopia (defined as -6 D or worse) dropped from 38% in the extrapolated single-vision lens control group to just 9% in the Essilor® Stellest® lenses group². This research further validates the ethical approach of using extrapolated control groups in long-term clinical trials evaluating myopia progression.

Dr. Björn Drobe, Director, Applied Myopia Research, EssilorLuxottica R&D, commented, “The six-year clinical data, along with other recent published studies, represent a significant step forward in understanding the full scope of how Essilor® Stellest® lenses manage myopia progression, further confirming their long-term efficacy and significant role in myopia management.”

Essilor® Stellest® lenses provide eye care practitioners with an evidence-backed solution for managing myopia in children and young adults. With robust clinical data supporting their efficacy, these lenses offer a reliable approach for helping families address the challenges of myopia, improving both short- and long-term eye health outcomes.